Langemed Secures Hundred-Million-Yuan Financing Led by Decheng Capital, China Renaissance as Exclusive Financial Advisor

Recently, Lange Medtech Group, a medical device company in the field of minimally invasive orthopedics in China, announced the completion of a new round of billion-level investment led by Decheng Capital.CRP-FANYA Investment Consultants(Beijing)Co.,Ltd. served as the exclusive financial advisor to Lange Medtech in the transaction.

Lange Medtech focuses on minimally invasive orthopedics, particularly in the design and development of products for minimally invasive spinal procedures, and is committed to providing comprehensive solutions for minimally invasive spine treatments. The core team at Lange Medtech has deep roots in China’s orthopedic industry, with an average of over 15 years of extensive experience in the field, primarily from leading companies in minimally invasive orthopedics such as MicroPort and Johnson & Johnson. Through their technical expertise and understanding of the industry, they are dedicated to developing a diverse range of products including minimally invasive spinal surgery consumables, endoscopic systems, bone cement, and energy platforms, covering areas such as osteoporotic vertebral compression fracture (OVCF) treatment, endoscopic treatment for simple disc pathologies, and minimally invasive treatments under arthroscopy. Additionally, the company has applied for more than 10 national patents and obtained 16 medical device registration certificates, including 4 Class III and 12 Class II registrations. Since 2018, the company has successively received multiple qualifications and titles such as Shanghai High-Tech Enterprise, "Specialized, Precise, Unique, and Innovative" enterprise, and Shanghai Standardization Pilot.

After this round of financing, Lange Medtech will focus on the existing field of minimally invasive spine surgery, planning to strategically acquire and integrate new technologies, products, and materials in the orthopedic field in the future. The company aims to form a multi-brand, multi-product strategy on the sales front, providing customers with more comprehensive solutions. This will help Lange Medtech penetrate the domestic market in China more quickly and effectively, accelerating the overall localization process of the industry.

Founder and CEO of Lange MedtechCEOZhou XinExpressed: "We are very grateful for Decheng Capital's recognition of the company and their support in driving the next phase of Lange Medtech’s strategic development. After completing this round of financing, Lange Medtech will not only deepen its commercial strategy to rapidly expand the market but also strategically consider external mergers and acquisitions to strengthen its presence in more innovative minimally invasive spinal products, orthopedic new materials, and other fields. This will create effective synergy for Lange Medtech across various specialized orthopedic solutions. In the future, Lange Medtech will also embark on a new journey of internationalization, achieving continuous growth and self-breakthrough. Along the way, we thank our long-term shareholders for their trust and support, and we hope to gain stronger support from Decheng Capital in both international and domestic markets as we move forward."

Decheng Capital Partner Wei XuStated: "Lange Medtech is a young, dynamic, and highly motivated medical device startup. Over the past decade, the company has grown through perseverance, gradually developing a comprehensive range of minimally invasive spinal solutions via self-researched production and collaborative partnerships. With boldness, the company has innovated its business model from traditional to cutting-edge, showing resilience and adaptability in an increasingly competitive orthopedic market. Currently, domestic brands are gaining strong momentum in the Chinese market. In the field of minimally invasive spine technology, there remains significant room for local substitution compared to other orthopedic subfields. Lange Medtech is poised to become a fast-growing leader among the new generation of companies in the spinal medical device industry, setting a benchmark for domestic orthopedic device brands. We hope this investment by Decheng Capital will support Lange Medtech’s long-term sustainable development, and we deeply appreciate Lange Medtech’s trust in Decheng Capital."

Jerry Xie, Managing Director of Huaxing Capital and Head of Healthcare and Life SciencesStated: "Thanks to the country's strong promotion of the development of domestically produced orthopedic devices, the localization of orthopedic devices has ushered in new market opportunities. Lange Medtech has already established a good reputation in the market through its high-quality products. In the highly competitive Chinese orthopedic market, Lange Medtech has gained support from well-known funds with international perspectives, such as Decheng Capital. We believe that it will continue to grow stronger in areas like subsequent product expansion, channel development, and mergers and acquisitions. CRP-FANYA Investment Consultants (Beijing) Co., Ltd. is honored to assist the company in completing this transaction, and we hope that Lange Medtech can create long-term value for doctors and patients."